Pressemeddelelse fra LEO Pharma
Ballerup, December 16, 2020 – LEO Pharma A/S today announced that Jörg Möller will join its Global Leadership Team as Executive Vice President, Global Research and Development, effective January 1, 2021.
Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pharma Executive Committee.
A medical doctor and Ph.D. by training, Jörg Möller brings a wealth of experience from his long international career during which he was responsible for a significant global organization with main hubs in Germany, the US, Switzerland, Japan and China. He led the entire value chain from target and drug discovery through clinical development, life-cycle-management and regulatory approvals and has brought a range of successful global product approvals. His experience spans multiple therapeutic areas including dermatology and immunology and a variety of technology platforms like biologics and cell & gene therapies. He has a solid track record of working with external partners.
“Jörg Möller’s experience will help us to significantly foster our innovative pipeline which underpins our ambition to become a global leader in medical dermatology,” said Catherine Mazzacco, President and CEO of LEO Pharma.
“I am excited to join LEO Pharma and inspired by its strategy and ambition. People with dermatologic medical conditions need new treatment options, and I want to bring in my experience and expertise to the R&D team at LEO Pharma so we together can contribute significantly to improving patients’ lives,” saidJörg Möller.
Jörg Möller succeeds Kim Kjøller who, as previously announced, decided to leave LEO Pharma for a CEO role at Union Therapeutics.
– Ends –
Kontakt:
Henrik Kyndlev
+45 3140 6180
hdtdk@leo-pharma.com
Læs hele pressemeddelelsen på Via Ritzau her: https://via.ritzau.dk/pressemeddelelse/leo-pharma-strengthens-global-leadership-team-with-appointment-of-jorg-moller-as-executive-vice-president-global-research-and-development?releaseId=13606546
** Ovenstående pressemeddelelse er videreformidlet af Ritzau på vegne af tredjepart. Ritzau er derfor ikke ansvarlig for indholdet **
